Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 1 · 25%High 1 · 25%

Atovaquone‐proguanil vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 28 (PCR‐adjusted) · children under 5 years of age

Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐amodiaquine (low certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 3.19 [0.67, 15.22]
1 study · 132 participants
Low

Atovaquone‐proguanil vs mefloquine plus artesunate (MQ + AS)

Total failure: day 42 (PCR‐adjusted) · children and adults

Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artesunate‐mefloquine (high certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 1.15 [0.57, 2.34]
2 studies · 1168 participants
High

Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil

Total failure: day 28 (PCR‐adjusted) · children and adults

Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (low certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 5.143 [0.61, 43.52]
2 studies · 375 participants
Low

Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil

Total failure: day 42 (PCR‐adjusted) · children and adults

Atovaquone‐proguanil showed no clear difference in total failure [day 42 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 1.84 [0.95, 3.56]
2 studies · 1258 participants
Moderate